{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T04:21:21Z","timestamp":1692764481133},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","immunology.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.iac.2017.01.013","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T11:50:43Z","timestamp":1490961043000},"page":"431-448","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Future Prospects of Biologic Therapies for Immunologic Diseases"],"prefix":"10.1016","volume":"37","author":[{"given":"Santhosh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brant R.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.iac.2017.01.013_bib1","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1172\/JCI37346","article-title":"Many cytokines are very useful therapeutic targets in disease","volume":"118","author":"Feldmann","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.iac.2017.01.013_bib2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.immuni.2008.03.005","article-title":"Cytokines as therapeutic targets: advances and limitations","volume":"28","author":"Scheinecker","year":"2008","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.iac.2017.01.013_bib3","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/jclinpath-2014-202493","article-title":"Gene of the month: interleukin 6 (IL-6)","volume":"67","author":"Ataie-Kachoie","year":"2014","journal-title":"J\u00a0Clin Pathol"},{"issue":"5","key":"10.1016\/j.iac.2017.01.013_bib4","first-page":"331","article-title":"Interleukin-6 and mast cells","volume":"23","author":"Conti","year":"2002","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"10.1016\/j.iac.2017.01.013_bib5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1172\/JCI200522433","article-title":"The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in\u00a0vivo","volume":"115","author":"Doganci","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.iac.2017.01.013_bib7","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.4049\/jimmunol.180.9.6317","article-title":"TLR2-mediated activation of neutrophils in response to German cockroach frass","volume":"180","author":"Page","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"10.1016\/j.iac.2017.01.013_bib8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1164\/rccm.200806-974OC","article-title":"Toll\/IL-1 signaling is critical for house dust mite-specific helper T\u00a0cell type 2 and type 17 [corrected] responses","volume":"179","author":"Phipps","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.iac.2017.01.013_bib9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jaci.2015.02.032","article-title":"Allergen-induced IL-6 trans-signaling activates \u03b3\u03b4 T\u00a0cells to promote type 2 and type 17 airway inflammation","volume":"136","author":"Ullah","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2017.01.013_bib10","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jaci.2016.03.010","article-title":"Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis\u2014PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology","volume":"137","author":"Muraro","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2017.01.013_bib11","doi-asserted-by":"publisher","first-page":"e01949","DOI":"10.7554\/eLife.01949","article-title":"T\u00a0cell-intrinsic role of IL-6 signaling in primary and memory responses","volume":"3","author":"Nish","year":"2014","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.iac.2017.01.013_bib12","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jaci.2011.09.009","article-title":"Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection","volume":"128","author":"Navarini","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2017.01.013_bib13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2014-09-602763","article-title":"Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations","volume":"125","author":"Milner","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.iac.2017.01.013_bib14","doi-asserted-by":"publisher","first-page":"20037","DOI":"10.18632\/oncotarget.5042","article-title":"A\u00a0novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation","volume":"6","author":"Wienke","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.iac.2017.01.013_bib15","unstructured":"Castro-Wagner JB, Kumar AR, Jolley C, et\u00a0al. Treatment with IL-6 blockade in patients with gain of function STAT3 mutations. In: Final Program of the Clinical Immunology Society 2016 Annual Meeting: Immune Deficiency & Dysregulation North American Conference. Boston (MA), 2016. p. 17."},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4161\/mabs.1.3.8593","article-title":"Ustekinumab","volume":"1","author":"Cingoz","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.iac.2017.01.013_bib17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fimmu.2012.00129","article-title":"TH17 cells in autoimmunity and immunodeficiency: protective or pathogenic?","volume":"3","author":"Marwaha","year":"2012","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/09546634.2013.782095","article-title":"Concurrent treatment of chronic psoriasis and asthma with ustekinumab","volume":"25","author":"Amarnani","year":"2014","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.iac.2017.01.013_bib19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1067\/mai.2003.1414","article-title":"Polarized in\u00a0vivo expression of IL-11 and IL-17 between acute and chronic skin lesions","volume":"111","author":"Toda","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5021\/ad.2013.25.3.368","article-title":"Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab","volume":"25","author":"Agusti-Mejias","year":"2013","journal-title":"Ann Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ad.2013.05.003","article-title":"Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients","volume":"105","author":"Fernandez-Anton Martinez","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"9","key":"10.1016\/j.iac.2017.01.013_bib22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/gut.2003.024190","article-title":"T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease","volume":"53","author":"Matsuoka","year":"2004","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib23","first-page":"823","article-title":"Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease","volume":"150","author":"Parronchi","year":"1997","journal-title":"Am J Pathol"},{"issue":"35","key":"10.1016\/j.iac.2017.01.013_bib24","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.3748\/wjg.v12.i35.5606","article-title":"Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication","volume":"12","author":"Peluso","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1756283X15618130","article-title":"Ustekinumab for the treatment of Crohn's disease: can it find its niche?","volume":"9","author":"Simon","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1053\/j.gastro.2006.06.022","article-title":"Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency","volume":"131","author":"Mannon","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.iac.2017.01.013_bib27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11894-016-0491-3","article-title":"Gastrointestinal disorders associated with common variable immune deficiency (CVID) and chronic granulomatous disease (CGD)","volume":"18","author":"Uzzan","year":"2016","journal-title":"Curr Gastroenterol Rep"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib28","doi-asserted-by":"publisher","first-page":"e0150018","DOI":"10.1371\/journal.pone.0150018","article-title":"A\u00a0study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus","volume":"11","author":"McKie","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1189\/jlb.0602313","article-title":"Interleukin-18","volume":"73","author":"Gracie","year":"2003","journal-title":"J\u00a0Leukoc Biol"},{"issue":"7","key":"10.1016\/j.iac.2017.01.013_bib30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1586\/1744666X.2015.1047765","article-title":"Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts","volume":"11","author":"Sarrabay","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"10.1016\/j.iac.2017.01.013_bib31","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1172\/JCI71543","article-title":"Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies","volume":"123","author":"Brydges","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bjh.14144","article-title":"Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options","volume":"174","author":"Brisse","year":"2016","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.iac.2017.01.013_bib33","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.iac.2017.01.013_bib34","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","article-title":"How I treat hemophagocytic lymphohistiocytosis in the adult patient","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4049\/jimmunol.160.1.299","article-title":"IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice","volume":"160","author":"Bohn","year":"1998","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib36","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1365-2141.1999.01504.x","article-title":"Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity","volume":"106","author":"Takada","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iac.2017.01.013_bib37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2012.00239","article-title":"Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein","volume":"3","author":"Chiossone","year":"2012","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J\u00a0Leukoc Biol"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib39","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T\u00a0cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.iac.2017.01.013_bib40","unstructured":"Jordan MB, Locatelli F, Allen C, et\u00a0al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH. In: Final Program of American Society of Hematology 57th Annual Meeting and Exposition. Orlando (FL), 2015."},{"key":"10.1016\/j.iac.2017.01.013_bib41","unstructured":"Jordan MB. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with NI-0501, an anti-interferon gamma monoclonal antibody. In: Final Program of the Clinical Immunology Society 2016 Annual Meeting: Immune Deficiency & Dysregulation North American Conference. Boston (MA), 2016. p. 17."},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.aller.2013.11.002","article-title":"A\u00a0human monoclonal anti-TNF alpha antibody (adalimumab) reduces airway inflammation and ameliorates lung histology in a murine model of acute asthma","volume":"43","author":"Catal","year":"2015","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11882-007-0013-3","article-title":"Tumor necrosis factor inhibitors for the treatment of asthma","volume":"7","author":"Kim","year":"2007","journal-title":"Curr Allergy Asthma Rep"},{"issue":"8","key":"10.1016\/j.iac.2017.01.013_bib45","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10038-006-0007-3","article-title":"An association between asthma and TNF-308G\/A polymorphism: meta-analysis","volume":"51","author":"Aoki","year":"2006","journal-title":"J\u00a0Hum Genet"},{"issue":"9","key":"10.1016\/j.iac.2017.01.013_bib46","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1172\/JCI80012","article-title":"Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade","volume":"125","author":"Buchbinder","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.iac.2017.01.013_bib48","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ni1178","article-title":"Naturally arising Foxp3-expressing CD25+CD4+ regulatory T\u00a0cells in immunological tolerance to self and non-self","volume":"6","author":"Sakaguchi","year":"2005","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jaci.2010.11.030","article-title":"Mechanisms of allergen-specific immunotherapy","volume":"127","author":"Akdis","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/cei.12041","article-title":"Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy","volume":"172","author":"Maazi","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"6204","key":"10.1016\/j.iac.2017.01.013_bib51","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"issue":"6246","key":"10.1016\/j.iac.2017.01.013_bib52","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.iac.2017.01.013_bib53","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaci.2015.08.036","article-title":"Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4","volume":"137","author":"Lee","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2017.01.013_bib55","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jamaophthalmol.2016.1013","article-title":"Assessment of CTLA-4 deficiency-related autoimmune choroidopathy response to abatacept","volume":"134","author":"Shields","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"13","key":"10.1016\/j.iac.2017.01.013_bib56","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaci.2007.11.030","article-title":"B\u00a0cell-directed therapies for autoimmune disease and correlates of disease response and relapse","volume":"121","author":"Levesque","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.iac.2017.01.013_bib58","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1365-4362.2001.01203.x","article-title":"Atopic dermatitis: immunophenotyping of inflammatory cells in skin lesions","volume":"40","author":"Lugovic","year":"2001","journal-title":"Int J Dermatol"},{"issue":"7","key":"10.1016\/j.iac.2017.01.013_bib59","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1398-9995.2005.00798.x","article-title":"Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment","volume":"60","author":"Simon","year":"2005","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib60","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/BF00412924","article-title":"The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis","volume":"278","author":"Bruynzeel-Koomen","year":"1986","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"10.1016\/j.iac.2017.01.013_bib61","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib62","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab) treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2017.01.013_bib63","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-032713-120222","article-title":"Anticytokine autoantibody-associated immunodeficiency","volume":"32","author":"Browne","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10.1016\/j.iac.2017.01.013_bib64","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10875-015-0201-1","article-title":"Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015","volume":"35","author":"Picard","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2017.01.013_bib65","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1183\/09031936.00160908","article-title":"Rituximab therapy in autoimmune pulmonary alveolar proteinosis","volume":"33","author":"Borie","year":"2009","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.iac.2017.01.013_bib66","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1182\/blood-2011-12-395707","article-title":"Anti-CD20 (rituximab) therapy for anti-IFN-gamma autoantibody-associated nontuberculous mycobacterial infection","volume":"119","author":"Browne","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2017.01.013_bib67","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/cid\/cit809","article-title":"Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-gamma autoantibody","volume":"58","author":"Czaja","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib68","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00018-015-2062-4","article-title":"The common gamma-chain cytokine receptor: tricks-and-treats for T\u00a0cells","volume":"73","author":"Waickman","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"10.1016\/j.iac.2017.01.013_bib69","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1172\/JCI25112","article-title":"Defective regulatory and effector T\u00a0cell functions in patients with FOXP3 mutations","volume":"116","author":"Bacchetta","year":"2006","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.iac.2017.01.013_bib70","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jaci.2005.08.036","article-title":"CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy","volume":"116","author":"Ryan","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2017.01.013_bib71","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/sji.12040","article-title":"Frequency and expression of inhibitory markers of CD4(+) CD25(+) FOXP3(+) regulatory T\u00a0cells in patients with common variable immunodeficiency","volume":"77","author":"Arandi","year":"2013","journal-title":"Scand J Immunol"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib72","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s10875-009-9351-3","article-title":"Frequency of Treg cells is reduced in CVID patients with autoimmunity and splenomegaly and is associated with expanded CD21lo B lymphocytes","volume":"30","author":"Arumugakani","year":"2010","journal-title":"J\u00a0Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.clim.2009.03.519","article-title":"Reduced frequency of CD4(+)CD25(HIGH)FOXP3(+) cells and diminished FOXP3 expression in patients with common variable immunodeficiency: a link to autoimmunity?","volume":"132","author":"Genre","year":"2009","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2017.01.013_bib74","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.iac.2017.01.013_bib75","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.iac.2017.01.013_bib76","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1172\/JCI40141","article-title":"Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice","volume":"120","author":"Brightbill","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.iac.2017.01.013_bib77","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.4049\/jimmunol.0902437","article-title":"Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells","volume":"184","author":"Chen","year":"2010","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.iac.2017.01.013_bib78","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.rmed.2010.07.011","article-title":"Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma","volume":"104","author":"Chanez","year":"2010","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.iac.2017.01.013_bib79","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2500\/108854194778816463","article-title":"Diagnosis and management of allergic bronchopulmonary aspergillosis","volume":"15","author":"Greenberger","year":"1994","journal-title":"Allergy Proc"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib80","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2017.01.013_bib81","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/thx.2010.153312","article-title":"Effects of omalizumab in Aspergillus-associated airway disease","volume":"66","author":"Perez-de-Llano","year":"2011","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib83","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/BOR.0b013e32834d85ce","article-title":"Churg-Strauss syndrome: update on pathophysiology and treatment","volume":"24","author":"Vaglio","year":"2012","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib84","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/ard.2011.155382","article-title":"IgG4 immune response in Churg-Strauss syndrome","volume":"71","author":"Vaglio","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib85","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/02770900701767704","article-title":"Churg-Strauss vasculitis in a patient treated with omalizumab","volume":"45","author":"Bargagli","year":"2008","journal-title":"J\u00a0Asthma"},{"issue":"5","key":"10.1016\/j.iac.2017.01.013_bib86","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejim.2007.09.001","article-title":"Churg-Strauss syndrome associated with omalizumab","volume":"19","author":"Puechal","year":"2008","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.iac.2017.01.013_bib87","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/art.39663","article-title":"Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data from 17 patients","volume":"68","author":"Jachiet","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.iac.2017.01.013_bib88","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2017.01.013_bib89","first-page":"162","article-title":"An update on the impact of Staphylococcus aureus enterotoxins in chronic sinusitis with nasal polyposis","volume":"43","author":"Zhang","year":"2005","journal-title":"Rhinology"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib90","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1398-9995.2010.02448.x","article-title":"Mucosal tissue polyclonal IgE is functional in response to allergen and SEB","volume":"66","author":"Zhang","year":"2011","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2017.01.013_bib91","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2017.01.013_bib92","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/ACI.0b013e32832d2bc7","article-title":"Stinging hymenoptera and mastocytosis","volume":"9","author":"Rueff","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2017.01.013_bib93","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient","volume":"65","author":"Douglass","year":"2010","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib94","first-page":"52","article-title":"Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy","volume":"45","author":"Paraskevopoulos","year":"2013","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2017.01.013_bib95","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/sj.clpt.6100063","article-title":"The prospects for \u201cpersonalized medicine\u201d in drug development and drug therapy","volume":"81","author":"Woodcock","year":"2007","journal-title":"Clin Pharmacol Ther"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856117300139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856117300139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T23:20:20Z","timestamp":1692746420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856117300139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0889856117300139"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2017.01.013","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future Prospects of Biologic Therapies for Immunologic Diseases","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2017.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}